Tirzepatide (Mounjaro) for Type 2 Diabetes
Medical Letter on Drugs and Therapeutics
; 64(1654):105-112b, 2022.
Article
in English
| EMBASE | ID: covidwho-2057513
ABSTRACT
The FDA has approved tirzepatide (Mounjaro - Lilly), a peptide hormone with activity at both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, to improve glycemic control in adults with type 2 diabetes. Tirzepatide, which is injected subcutaneously once weekly, is the fi rst dual GIP/GLP-1 receptor agonist to become available in the US. Selective GIP receptor agonists are not available in the US;GLP-1 receptor agonists have been available for years. Copyright © 2022, Medical Letter Inc.. All rights reserved.
abdominal pain/si [Side Effect]; acute kidney failure/si [Side Effect]; acute pancreatitis/si [Side Effect]; anaphylaxis/si [Side Effect]; angioneurotic edema/si [Side Effect]; article; body weight loss; cardiovascular risk; chill/si [Side Effect]; cholelithiasis/si [Side Effect]; constipation/si [Side Effect]; coronavirus disease 2019; decreased appetite/si [Side Effect]; diarrhea/si [Side Effect]; drug approval; drug contraindication; drug efficacy; drug hypersensitivity/si [Side Effect]; drug indication; drug labeling; drug mechanism; drug potentiation; drug response; dyspepsia/si [Side Effect]; erythema/si [Side Effect]; evening dosage; excessive daytime sleepiness/si [Side Effect]; fatigue/si [Side Effect]; fever/si [Side Effect]; gallbladder disease/si [Side Effect]; glycemic control; groups by age; hallucination/si [Side Effect]; headache/si [Side Effect]; human; immunization; immunogenicity; injection site pain/si [Side Effect]; injection site reaction/si [Side Effect]; injection site swelling/si [Side Effect]; insomnia/dt [Drug Therapy]; lactation; loss of appetite/si [Side Effect]; lymphadenopathy/si [Side Effect]; maintenance therapy; myalgia/si [Side Effect]; myocarditis/si [Side Effect]; non insulin dependent diabetes mellitus/dt [Drug Therapy]; onset age; outcome assessment; parasomnia/si [Side Effect]; pregnancy; risk reduction; sleep latency; sleep quality; sleep time; somnolence/si [Side Effect]; swelling/si [Side Effect]; treatment duration; treatment outcome; vomiting/si [Side Effect]; cilgavimab plus tixagevimab/ae [Adverse Drug Reaction]; cytochrome P450 3A inhibitor/cb [Drug Combination]; cytochrome P450 3A inhibitor/it [Drug Interaction]; daridorexant/ae [Adverse Drug Reaction]; daridorexant/ct [Clinical Trial]; daridorexant/cb [Drug Combination]; daridorexant/cm [Drug Comparison]; daridorexant/it [Drug Interaction]; daridorexant/dt [Drug Therapy]; daridorexant/pd [Pharmacology]; doxepin/dt [Drug Therapy]; dulaglutide; elasomeran/ae [Adverse Drug Reaction]; eszopiclone/dt [Drug Therapy]; glucagon like peptide 1 receptor agonist/dt [Drug Therapy]; liraglutide; mirtazapine/dt [Drug Therapy]; oral contraceptive agent/cm [Drug Comparison]; oral contraceptive agent/it [Drug Interaction]; placebo; SARS-CoV-2 vaccine; semaglutide; tirzepatide/ae [Adverse Drug Reaction]; tirzepatide/ct [Clinical Trial]; tirzepatide/cm [Drug Comparison]; tirzepatide/it [Drug Interaction]; tirzepatide/dt [Drug Therapy]; tirzepatide/pd [Pharmacology]; tirzepatide/sc [Subcutaneous Drug Administration]; tozinameran/ae [Adverse Drug Reaction]; tozinameran/im [Intramuscular Drug Administration]; trazodone/dt [Drug Therapy]; zolpidem/dt [Drug Therapy]; axillary swelling/si [Side Effect]; groin swelling/si [Side Effect]
Search on Google
Collection:
Databases of international organizations
Database:
EMBASE
Language:
English
Journal:
Medical Letter on Drugs and Therapeutics
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS